Onco Wiki / Maladie

Carcinome à cellules squamo-dentales (HNSCC)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-HNSCC
TypeMaladie
Alias
HNSCCCarcinome à cellules squamouses de la tête et du couSCCHNПлоскоклітинна карцинома голови та шиї
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-NSCLC-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8070/3
icd_o_3_topography["C00", "C01", "C02", "C03", "C04", "C05", "C06", "C07", "C08", "C09", "C10", "C11", "C12", "C13", "C14", "C30", "C31", "C32"]
icd_10C00-C14, C30-C32
who_classificationWHO Head and Neck Tumours 5th ed (2024): Squamous cell carcinoma of upper aerodigestive tract

Capacités

Notes

Two distinct biologies under one disease entity: HPV+ oropharyngeal: typically tonsil / base of tongue; younger patients; better prognosis; AJCC 8 separate staging system; active de-escalation trials (cisplatin-light or radiation-light protocols). HPV− (tobacco / alcohol): higher TP53 / CDKN2A mutation burden; worse prognosis; standard intensification. Therapy: - Localized: surgery (oral cavity preferred when feasible) ± adjuvant chemoRT; or concurrent cisplatin-RT (definitive); or induction + chemoRT (selected hypopharynx / larynx preservation). - Recurrent / metastatic 1L: * PD-L1 CPS ≥20: pembrolizumab monotherapy (KEYNOTE-048). * PD-L1 CPS ≥1: pembrolizumab + 5-FU + platinum (KEYNOTE-048 chemo-IO). * EXTREME (cetuximab + 5-FU + platinum) remains alternative. - 2L+: nivolumab (CheckMate-141) if IO-naive; cetuximab monotherapy / methotrexate / docetaxel. - Genotype-driven (investigational / accelerated): * HRAS mutant (~6-8%): tipifarnib (FDA breakthrough designation; AIM-HN phase 3 ongoing). * NTRK fusion (rare): larotrectinib / entrectinib. * BRAF V600E (very rare): dabrafenib + trametinib. Cetuximab (anti-EGFR mAb) has activity irrespective of EGFR mutational status — small-m...

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources